Streetbeat News

Products Services

THQQF

Embracer Group plans to leverage the 'Lord of the Rings' franchise to create a significant gaming presence, amid restructuring and layoffs. The company will close multiple studios and cancel several games, following a failed $2 billion deal. Embracer Group also holds the rights to the 'Tomb Raider' franchise.

Portfolio Pulse from Franca Quarneti

June 15, 2023 | 8:21 pm

MRCY

Mercury Systems introduces ROCK 4, a safety certifiable, small-form factor, ruggedized mission computer with the latest 11th gen Intel Core i7 processors for aerospace and defense missions.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:17 pm

SPCE

Virgin Galactic announces the start of its commercial spaceflight service, with the first flight 'Galactic 01' scheduled between June 27-30, 2023, followed by 'Galactic 02' in early August 2023, and monthly spaceflights thereafter.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:16 pm

AZN

BNTX

JNJ

MRNA

NVAX

PFE

U.S. FDA advisers have voted unanimously in favor of XBB-tailored Covid-19 vaccines for the 2023-24 vaccination campaign. Companies like AZN, BNTX, JNJ, MRNA, NVAX, and PFE may be involved.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:11 pm

STXS

Stereotaxis (STXS) is set to initiate the first-in-human trial to support the CE Mark application of its MAGiC Catheter, a robotic magnetic navigation technology for cardiac procedures.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:10 pm

SLS

SELLAS Life Sciences Group's abstract has been accepted for presentation at the International Gynecologic Cancer Society Annual Meeting, showcasing their research in gynecologic cancer.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:10 pm

XAIR

Beyond Air has licensed commercial rights for neuronal nitric oxide synthase (nNOS) inhibitors for autism spectrum disorder (ASD) treatment from Hebrew University of Jerusalem. The preclinical results show a reversal of ASD phenotypes, and a first-in-human clinical trial is planned for 2025.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:09 pm

ENVX

Enovix Corporation (NASDAQ: ENVX) has achieved its Q2 forecast of 18,000 units manufactured at its Fab1 location and expects to exceed its quarterly guidance. The company maintains its FY23 target of producing 180,000 cells for customers from Fab1. Enovix plans to begin high-volume manufacturing at its Fab2 location in Malaysia next year.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:05 pm

ENVX

Enovix Corporation (NASDAQ: ENVX) has achieved its Q2 forecast of 18,000 units manufactured at its Fab1 location in Fremont and expects to exceed its quarterly guidance with more than two weeks remaining in the quarter. The company plans to produce 180,000 cells in 2023 and start high-volume manufacturing at its Fab2 location in Malaysia next year.

Portfolio Pulse from Happy Mohamed

June 15, 2023 | 8:04 pm

NIO

NIO has launched its first smart electric tourer, the ET5 Touring, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 8:04 pm